{
    "clinical_study": {
        "@rank": "56933", 
        "arm_group": [
            {
                "arm_group_label": "Treatment ABCD", 
                "arm_group_type": "Experimental", 
                "description": "The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:\nTreatment A: Tiotropium HFA BAI 4.5 mcg/day\nTreatment B: Tiotropium HFA BAI 9.0 mcg/day\nTreatment C: SPIRIVA\u00ae HandiHaler\u00ae 18 mcg/day\nTreatment D: Spiriva\u00ae Respimat\u00ae 5 mcg/day"
            }, 
            {
                "arm_group_label": "Treatment BDAC", 
                "arm_group_type": "Experimental", 
                "description": "The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:\nTreatment B: Tiotropium HFA BAI 9.0 mcg/day\nTreatment D: Spiriva\u00ae Respimat\u00ae 5 mcg/day\nTreatment A: Tiotropium HFA BAI 4.5 mcg/day\nTreatment C: SPIRIVA\u00ae HandiHaler\u00ae 18 mcg/day"
            }, 
            {
                "arm_group_label": "Treatment CADB", 
                "arm_group_type": "Experimental", 
                "description": "The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:\nTreatment C: SPIRIVA\u00ae HandiHaler\u00ae 18 mcg/day\nTreatment A: Tiotropium HFA BAI 4.5 mcg/day\nTreatment D: Spiriva\u00ae Respimat\u00ae 5 mcg/day\nTreatment B: Tiotropium HFA BAI 9.0 mcg/day"
            }, 
            {
                "arm_group_label": "Treatment DCBA", 
                "arm_group_type": "Experimental", 
                "description": "The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:\nTreatment D: Spiriva\u00ae Respimat\u00ae 5 mcg/day\nTreatment C: SPIRIVA\u00ae HandiHaler\u00ae 18 mcg/day\nTreatment B: Tiotropium HFA BAI 9.0 mcg/day\nTreatment A: Tiotropium HFA BAI 4.5 mcg/day"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to assess and compare the pharmacokinetics (PK) of\n      Tiotropium delivered via Breath Actuated Inhaler (BAI) (4.5 mcg/day or 9.0 mcg/day),\n      SPIRIVA\u00ae, HandiHaler\u00ae, (18 mcg/day) and Respimat\u00ae Soft Mist\u2122  Inhaler (SMI) (5.0 mcg/day)\n      following repeat dosing for 7 days in subjects with COPD."
        }, 
        "brief_title": "To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "COPD", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "This multicenter study consists of a Screening Visit (3 to 14 days prior to randomization);\n      4 multiple-dose (7-day) Treatment Periods, each consisting of a 2-night/3-day inpatient stay\n      (Day 6 to Day 8); and a Final Visit. A washout period of at least 21 days will occur between\n      each Treatment Period. The Final/ Early Termination Visit will occur 6-8 days following the\n      last Treatment Period or upon early discharge from the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written informed consent signed and dated by the subject before conducting any study\n             related procedure\n\n          2. Male or female subjects 40 -80 years of age, as of the Screening Visit\n\n          3. Diagnosis of COPD as defined by the GOLD (Global Initiative for Chronic Obstructive\n             Lung Disease) Guidelines\n\n          4. A pre-bronchodilator Peak Inspiratory Flow (PIF) rate\u2265 30 L/ min as measured with the\n             In-Check\u2122 DIAL training device.\n\n          5. A measured post-bronchodilator (ipratropium bromide) forced expiratory volume in one\n             second (FEV1) >30% and <80% of predicted normal for height, age and gender at the\n             Screening Visit (SV). Third National Health and Nutrition Examination Survey\n             1988-1994 (NHANES III) predicted values will be used and adjustments to predicted\n             values will be made for African-American subjects.\n\n          6. A measured post-bronchodilator (ipratropium bromide) FEV1/Forced Vital Capacity (FVC)\n             <0.70 at the Screening Visit (SV)\n\n          7. If female, is currently not pregnant, breast feeding, or attempting to become\n             pregnant (for 4 weeks before the Screening Visit (SV) and throughout the duration of\n             the study), and is of\n\n               -  Non-childbearing potential, defined as:\n\n                    -  \u22651 year post-menopausal or\n\n                    -  Surgically sterile (tubal ligation, bilateral oophorectomy, salpingectomy,\n                       or hysterectomy) or is of\n\n               -  Childbearing potential, has a negative serum pregnancy test, and is willing to\n                  commit to using a consistent and acceptable method of birth control as defined\n                  below for the duration of the study:\n\n                    -  Systemic contraception used for \u22651 month prior to screening, including\n                       birth control pills, transdermal patch, vaginal ring, implants, or\n                       injectables or\n\n                    -  Double barrier methods (condoms, cervical cap, diaphragm, and vaginal\n                       contraceptive film with spermicide) or\n\n                    -  Intrauterine device (IUD) with a low failure rate defined as <1% per year\n                       (use of copper IUDs are excluded) or is of\n\n                         -  Childbearing potential and not sexually active, has a negative serum\n                            pregnancy test, and is willing to commit to using a consistent and\n                            acceptable method of birth control as defined above for the duration\n                            of the study, in the event the subject becomes sexually active\n\n          8. Current or ex-smoker with \u226510 pack-year smoking history\n\n          9. Subject is free of any concomitant conditions or treatment that could interfere with\n             study conduct, influence the interpretation of study observations/results, or put the\n             subject at increased risk during the study\n\n         10. Able to perform technically acceptable and reproducible spirometry per study\n             guidelines as defined in the protocol and study procedures manual.\n\n         11. Able to demonstrate the proper inhalation techniques required for correct use of all\n             delivery devices required in the study\n\n         12. Capable of understanding the requirements, risks, and benefits of study\n             participation, and, as judged by the investigator, capable of giving informed consent\n             and being compliant with all study requirements\n\n        Exclusion Criteria:\n\n          1. Pregnancy, nursing, or plans to become pregnant or donate gametes (ova or sperm) for\n             in vitro fertilization during the study period or for 30 days following the subject's\n             last study related visit (for eligible subjects only, if applicable).\n\n          2. History or current evidence (as determined by medical history, physical examination,\n             clinical laboratory assessments and ECG) of a clinically significant or uncontrolled\n             disease including, but not limited to: cardiovascular (e.g., uncontrolled\n             hypertension, congestive heart failure, known aortic aneurysm, clinically significant\n             cardiac arrhythmia or coronary heart disease), hepatic, renal, haematological,\n             neuropsychological, endocrine (e.g., uncontrolled diabetes mellitus, uncontrolled\n             thyroid disorder, Addison's disease, Cushing's syndrome), gastrointestinal (e.g.,\n             poorly controlled peptic ulcer, gastroesophageal reflux disease) or pulmonary (other\n             than COPD such as asthma, sarcoidosis, non-cystic fibrosis (CF) bronchiectasis,\n             cystic fibrosis, bronchopulmonary dysplasia or a diagnosis of alpha 1-antitrypsin\n             deficiency). Significant is defined as any disease that, in the opinion of the\n             investigator, would put the safety of the subject at risk through participation, or\n             which could affect the endpoint analysis if the disease/condition exacerbated during\n             the study.\n\n          3. History of and/or current diagnosis of asthma\n\n          4. History of a life-threatening COPD exacerbation - defined for this protocol as a COPD\n             episode that required intubation and/or was associated with hypercapnia, respiratory\n             arrest or hypoxic seizures\n\n          5. Thoracotomy with pulmonary resection\n\n          6. Current congestive heart failure, history or current evidence of myocardial\n             infarction (within 3 yrs of the Screening Visit [SV]), or history or current evidence\n             of ischemic heart disease, including a diagnosis on screening ECG.\n\n          7. History or current evidence of clinically significant cardiac arrhythmia, including a\n             diagnosis on screening ECG.\n\n          8. Presence of angle-closure glaucoma\n\n          9. History of malignancy (excluding basal cell carcinoma) within the past 5 years,\n             regardless of the clinical significance or current stability of the disease\n\n         10. Known history or any current evidence of renal impairment or urinary retention (e.g.,\n             bladder outlet obstruction). This includes abnormal renal function test results at\n             screening.\n\n         11. Presence of symptomatic prostatic hyperplasia\n\n         12. History of silent infections, including positive tests for human immunodeficiency\n             virus 1, human immunodeficiency virus 2, Hepatitis B, Hepatitis C, or tuberculosis.\n\n         13. Occurrence of any upper or lower respiratory infection, including but not limited to\n             the common cold and flu, sinusitis,tonsillitis, pneumonia, bronchitis, or an ear\n             infection (including otitis media and externa) which is not resolved by 14 days prior\n             to randomization\n\n         14. Occurrence of a COPD exacerbation which is not resolved by 14 days prior to\n             randomization i. Note: An exacerbation of COPD is defined as any worsening of the\n             subject's baseline COPD symptoms requiring any treatment other than rescue\n             albuterol/salbutamol/ipratropium or the subject's regular maintenance treatment. This\n             includes requiring the use of systemic corticosteroids and/or emergency room visit or\n             hospitalization, a change in subject's regular, or the addition of other medications\n             used to treat COPD symptoms.\n\n         15. Subjects who require oxygen therapy and in the investigator's opinion, will be unable\n             to abstain from the use of oxygen therapy during testing\n\n         16. Subjects who have started or stopped an exercise rehabilitation program within 4\n             weeks of the Screening Visit (SV)\n\n         17. Known or suspected hypersensitivity or idiosyncratic reaction to tiotropium, or to\n             any ingredients used in the study medication formulations\n\n         18. Severe allergy to milk protein\n\n         19. Significant adverse drug reactions, including allergy or hypersensitivity reactions,\n             to atropine or any anticholinergic substance related pharmacologically to atropine\n             (e.g., ipratropium or oxitropium)\n\n         20. Use of any prohibited concomitant medications within the prescribed (per protocol)\n             withdrawal periods prior to the Screening Visit\n\n         21. Treatment with orally administered (excluding orally inhaled) \u03b2-adrenergics (i.e.,\n             oral salbutamol)\n\n         22. Treatment with \u03b2-adrenergic receptor antagonists (e.g. non-selective \u03b2-receptor\n             blocking agents like \u03b2-blocking anti-hypertensive products) administered by any\n             route. The single exception is that cardioselective \u03b21-adrenergic receptor\n             antagonists (e.g. atenolol, metoprolol, bisoprolol) are permitted provided that\n             subjects have been on a stable dose for at least 1 week prior to the screening visit\n             and subjects are expected to be able to maintain the same dose throughout the study.\n\n         23. Treatment with drugs commonly recognized to prolong the QTc interval (e.g.,\n             quinolones, amiodarone, disopyramide, quinidine, sotalol, chlorpromazine,\n             haloperidol, ketoconazole, terfenadine, cisapride and terodiline)\n\n         24. Treatment with any known cytochrome P450 (CYP) 2D6 or cytochrome P450 (CYP) 3A4\n             inhibitors (e.g., quinidine, ketoconazole and gestodene) within 30 days prior to the\n             Screening Visit (SV)\n\n         25. Initiation or change in dose of inhaled corticosteroids within the last 6 weeks prior\n             to the Screening Visit (SV), and /or not expected to maintain a stable dose of\n             inhaled corticosteroids during the course of the study.\n\n         26. Initiation or change in dose of oral or systemic corticosteroids within the last 6\n             weeks prior to the Screening Visit (SV) , unable to maintain a stable dose of oral or\n             systemic corticosteroids during the course of the study, or a dose of oral or\n             systemic corticosteroids in excess of the equivalent of 10 mg of prednisone per day.\n             [Note that oral steroid bursts completed 6 weeks or more prior to screening are\n             acceptable.]\n\n         27. Exposure to any investigational drug within 30 days or six half-lives (whichever is\n             greater) prior to the Screening Visit (SV)\n\n         28. Plans to donate or has donated plasma or blood within 1 month prior to the Screening\n             Visit (SV). This does not include small blood volumes taken for diagnostic purposes.\n             Plans to donate plasma or blood within 3 months following study completion\n\n         29. Has a history of alcohol and/or substance abuse within the past 5 years\n\n         30. Vulnerable subjects (e.g., persons kept in detention)\n\n         31. The subject is an employee of the study site or has an immediate family member or\n             household member involved with the conduct of the study (including participation in\n             the study)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01785433", 
            "org_study_id": "TBB-COPD-201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment ABCD", 
                    "Treatment BDAC", 
                    "Treatment CADB", 
                    "Treatment DCBA"
                ], 
                "intervention_name": "Tiotropium HFA BAI 4.5 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment ABCD", 
                    "Treatment BDAC", 
                    "Treatment CADB", 
                    "Treatment DCBA"
                ], 
                "intervention_name": "Tiotropium HFA BAI 9.0 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment ABCD", 
                    "Treatment BDAC", 
                    "Treatment CADB", 
                    "Treatment DCBA"
                ], 
                "intervention_name": "SPIRIVA\u00ae HandiHaler\u00ae 18 mcg/day", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment ABCD", 
                    "Treatment BDAC", 
                    "Treatment CADB", 
                    "Treatment DCBA"
                ], 
                "intervention_name": "Spiriva\u00ae Respimat\u00ae 5 mcg/day", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tiotropium"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "COPD, pharmacokinetics, tiotropium", 
        "lastchanged_date": "January 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "Teva Investigational Site 32170"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gauting", 
                        "country": "Germany"
                    }, 
                    "name": "Teva Investigational Site 32169"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grosshansdorf", 
                        "country": "Germany"
                    }, 
                    "name": "Teva Investigational Site 32171"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mannheim", 
                        "country": "Germany"
                    }, 
                    "name": "Teva Investigational Site 32167"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wiesbaden", 
                        "country": "Germany"
                    }, 
                    "name": "Teva Investigational Site 32168"
                }
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Open-Label, Repeat Dosing, Four-Period Crossover Study to Compare the Pharmacokinetics, Efficacy and Safety of Tiotropium Bromide Delivered Via Breath Actuated Inhaler (BAI), SPIRIVA\u00ae HandiHaler\u00ae and Respimat\u00ae Soft Mist\u2122 Inhaler (SMI) in Subjects With COPD", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "To evaluate the PK of Tiotropium Hydrofluoroalkane (HFA)  Breath Actuated Inhaler (BAI) (4.5 mcg/day and 9 mcg/day) to SPIRIVA\u00ae HandiHaler\u00ae and Spiriva\u00ae Respimat\u00ae", 
                "measure": "Area under the plasma concentration-time curve (AUC0-24h)", 
                "safety_issue": "No", 
                "time_frame": "From time 0 to 24 hours on Day 7"
            }, 
            {
                "description": "To evaluate the PK of Tiotropium HFA BAI (4.5 mcg/day and 9 mcg/day) to SPIRIVA\u00ae HandiHaler\u00ae and Spiriva\u00ae Respimat\u00ae", 
                "measure": "Maximum observed plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "From time 0 to 24 hours on Day 7"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01785433"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the PK of Tiotropium HFA BAI (4.5 mcg/day and 9 mcg/day) to SPIRIVA\u00ae HandiHaler\u00ae and Spiriva\u00ae Respimat\u00ae", 
                "measure": "Area under the plasma concentration-time curve (AUC 0-t)", 
                "safety_issue": "No", 
                "time_frame": "From time 0 to the time of the last quantifiable concentration as measured up to 24 hrs on Day 7"
            }, 
            {
                "description": "To evaluate the PK of Tiotropium HFA BAI (4.5 mcg/day and 9 mcg/day) to SPIRIVA\u00ae HandiHaler\u00ae and Spiriva\u00ae Respimat\u00ae", 
                "measure": "Time at which the maximum plasma concentration was observed (tmax)", 
                "safety_issue": "No", 
                "time_frame": "From time 0 to 24 hours on Day 7"
            }, 
            {
                "description": "The adverse event frequency, intensity, severity and relationship to the study drug will be recorded.", 
                "measure": "Occurrence of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "From signing of the Informed Consent Form until the final visit (approximately 6 to 8 days following the last treatment period)"
            }
        ], 
        "source": "Teva Pharmaceutical Industries", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Teva Pharmaceutical Industries", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}